{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inflammation+and+Pain+Following+Ocular+Surgery&page=2",
    "query": {
      "condition": "Inflammation and Pain Following Ocular Surgery",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inflammation+and+Pain+Following+Ocular+Surgery&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T23:09:23.597Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02128113",
      "title": "RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Corneal Endothelial Cell Loss",
        "Ocular Pain",
        "Ocular Inflammation",
        "Cataract Surgery"
      ],
      "interventions": [
        {
          "name": "Vehicle Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Omaveloxolone Ophthalmic Suspension 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Omaveloxolone Ophthalmic Suspension 1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 307,
      "start_date": "2014-05-31",
      "completion_date": "2015-04-30",
      "has_results": true,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-07-23T23:09:23.597Z",
      "location_count": 15,
      "location_summary": "Laguna Hills, California • Lancaster, California • Cape Coral, Florida + 11 more",
      "locations": [
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Cape Coral",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Hoffman Estates",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02128113"
    },
    {
      "nct_id": "NCT02065375",
      "title": "RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Inflammation and Pain Following Ocular Surgery"
      ],
      "interventions": [
        {
          "name": "Omaveloxolone Ophthalmic Suspension 1.0%",
          "type": "DRUG"
        },
        {
          "name": "Omaveloxolone Opthalmic Suspension 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 109,
      "start_date": "2014-02-28",
      "completion_date": "2014-09-30",
      "has_results": true,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-07-23T23:09:23.597Z",
      "location_count": 6,
      "location_summary": "Garden Grove, California • Fort Myers, Florida • Kansas City, Missouri + 3 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Elizabeth City",
          "state": "North Carolina"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02065375"
    },
    {
      "nct_id": "NCT01996839",
      "title": "Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Inflammation",
        "Pain",
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Loteprednol Etabonate Gel (BID)",
          "type": "DRUG"
        },
        {
          "name": "Loteprednol Etabonate Gel (TID)",
          "type": "DRUG"
        },
        {
          "name": "Vehicle (BID)",
          "type": "DRUG"
        },
        {
          "name": "Vehicle (TID)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 514,
      "start_date": "2013-12",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2020-09-25",
      "last_synced_at": "2026-07-23T23:09:23.597Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01996839"
    },
    {
      "nct_id": "NCT01591655",
      "title": "Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract",
        "Inflammation",
        "Surgery"
      ],
      "interventions": [
        {
          "name": "Mapracorat",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 360,
      "start_date": "2012-07",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2020-09-03",
      "last_synced_at": "2026-07-23T23:09:23.597Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01591655"
    },
    {
      "nct_id": "NCT04539548",
      "title": "A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Dextenza Ophthalmic Insert",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone acetate ophthalmic suspension USP 1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ocular Therapeutix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "0 Years to 5 Years"
      },
      "enrollment_count": 65,
      "start_date": "2020-09-04",
      "completion_date": "2023-12-21",
      "has_results": false,
      "last_update_posted_date": "2024-04-15",
      "last_synced_at": "2026-07-23T23:09:23.597Z",
      "location_count": 14,
      "location_summary": "Aurora, Colorado • Fort Collins, Colorado • Jacksonville, Florida + 11 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04539548"
    },
    {
      "nct_id": "NCT04739709",
      "title": "Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Inflammation and Pain"
      ],
      "interventions": [
        {
          "name": "APP13007, 0.05%",
          "type": "DRUG"
        },
        {
          "name": "Matching Vehicle Placebo for APP13007, 0.05%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Formosa Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 378,
      "start_date": "2021-01-11",
      "completion_date": "2022-03-17",
      "has_results": true,
      "last_update_posted_date": "2023-07-20",
      "last_synced_at": "2026-07-23T23:09:23.597Z",
      "location_count": 34,
      "location_summary": "Scottsdale, Arizona • Glendale, California • Hemet, California + 28 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Hemet",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04739709"
    },
    {
      "nct_id": "NCT02786901",
      "title": "LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract",
        "Pain",
        "Ocular Inflammation"
      ],
      "interventions": [
        {
          "name": "Loteprednol Etabonate Ophthalmic Gel dosed TID",
          "type": "DRUG"
        },
        {
          "name": "Loteprednol Etabonate Ophthalmic Gel dosed BID",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2016-06",
      "completion_date": "2017-07-01",
      "has_results": true,
      "last_update_posted_date": "2021-01-08",
      "last_synced_at": "2026-07-23T23:09:23.597Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Oceanside, California • Miami, Florida + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Quincy",
          "state": "Massachusetts"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02786901"
    },
    {
      "nct_id": "NCT04089735",
      "title": "A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ocular Inflammation and Pain After Cataract Surgery"
      ],
      "interventions": [
        {
          "name": "APP13007, 0.05%",
          "type": "DRUG"
        },
        {
          "name": "APP13007, 0.1%",
          "type": "DRUG"
        },
        {
          "name": "APP13007 Placebo, 0.05%",
          "type": "DRUG"
        },
        {
          "name": "APP13007 Placebo, 0.1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Formosa Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2019-08-13",
      "completion_date": "2020-04-07",
      "has_results": true,
      "last_update_posted_date": "2023-06-27",
      "last_synced_at": "2026-07-23T23:09:23.597Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • Inglewood, California • Rancho Cordova, California + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Rancho Cordova",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04089735"
    },
    {
      "nct_id": "NCT01666210",
      "title": "Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ocular Inflammation and Pain"
      ],
      "interventions": [
        {
          "name": "OTX-DP (Dexamethasone punctum plug)",
          "type": "DRUG"
        },
        {
          "name": "Placebo Vehicle Punctum Plug",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ocular Therapeutix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2012-10",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2021-10-19",
      "last_synced_at": "2026-07-23T23:09:23.597Z",
      "location_count": 1,
      "location_summary": "Hoffman Estates, Illinois",
      "locations": [
        {
          "city": "Hoffman Estates",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01666210"
    },
    {
      "nct_id": "NCT01230125",
      "title": "Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Mapracorat",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 311,
      "start_date": "2010-11",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2020-09-03",
      "last_synced_at": "2026-07-23T23:09:23.597Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01230125"
    }
  ]
}